See all indications
Request personal visitSubscribe to AZ E-Informationservice
Share
BTC
BTCTOPAZ-1

IMFINZI® + gem-cis
1st line treatment of advanced or metastatic BTC1

uHCC
uHCCHIMALAYA

IMJUDO® + IMFINZI®
1st line treatment of unresectable HCC2

BTC=biliary tract cancer; cis=cisplatin; gem=gemcitabin; HCC=hepatocellular carcinoma; uHCC= unresectable hepatocellular carcinoma.

Therapeutic indication

IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin is indicated for the first line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC).1

IMJUDO® in combination with IMFINZI® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), who have not received prior systemic therapy.2

IMFINZI® Product Information

For more information, please consult the IMFINZI® Product Information (PI) in German, in French or in Italian.

IMJUDO® Product Information

For more information, please consult the IMJUDO® Product Information (PI) in German, in French or in Italian.

References

  1. IMFINZI® Information for Healthcare Professionals. www.swissmedicinfo.ch.
  2. IMJUDO® Information for Healthcare Professionals. www.swissmedicinfo.ch.

Professionals can request the mentioned references from AstraZeneca AG.

You are now leaving the IMFINZI website of AstraZeneca Switzerland

You are now leaving the IMFINZI website of AstraZeneca Switzerland and thus our area of responsibility. The linked pages possess their own terms of use and are possibly subject to other legislation and standards.

Continue